Diagnomics Partners With Translational Software to Launch Pharmacogenetic Testing Services in the United States

SAN DIEGO, October 15, 2018 (Newswire.com) - Diagnomics Inc., a San Diego-based genomics solution provider, has extended its product portfolio to include pharmacogenetic (PGx) reporting through a strategic partnership with Translational Software Inc. (TSI). Diagnomics is one of the first companies to offer clinically validated PGx solutions on Illumina’s Global Screening Array.

With over 710,000 genetic markers included in each genetic test, Diagnomics employs TSI’s high-throughput, evidence-based PGx platform to generate a comprehensive report on the tested individual’s anticipated drug response, metabolism and medication efficacy. The PGx report serves as a guide for both physicians and patients interested in pursuing a proactive approach and personalized experience with prescription drugs.

“We are delighted by our collaboration with TSI to bring forth the capability of genetic testing to support precision medicine,” Byung-In Lee, Ph.D., CEO of Diagnomics announced. “Our teams invested a tremendous amount of time and effort to ensure the report’s validation and viability that pertain to the individual patient. We hope that the report will encourage more patients and doctors to put more emphasis on preventive care and personalized medicine.”

”The partnership between our companies is another step to help further expand the field of pharmacogenetics and make genomics a standard clinical practice across a broad range of medications and diseases,” stated Don Rule, CEO of TSI. “The Diagnomics team has applied innovative strategies to make an expansive test panel both accessible and affordable for clinical use. We are looking forward to working together to realize the promise of this technology to improve precision health on a global basis.”

The visual, decision-ready PGx report offered by Diagnomics includes actionable items such as dosing guidance, potentially impacted medications and clinical consequences. Reports provide citations to the most recent drug labels, consortia guidelines and relevant research regarding drug safety and efficacy. The report also features a detachable card containing PGx results that the patient can conveniently carry on their person.

Diagnomics intends to work closely with TSI to develop targeted reports for pain, cancer and cardiovascular medications. These customized reports, in addition to the comprehensive version, will provide valuable insights on how patients respond to opioids, anticoagulants, statins, chemotherapies, etc., and promote patients’ curated treatment plans.

“The U.S. Food and Drug Administration reports that over two million of patients are suffering from serious adverse drug reactions yearly and the estimate of the cost of drug-related morbidity and mortality is $136 billion annually, which is more than the total cost of cardiovascular or diabetic care in the United States,” Min Seob Lee, Ph.D., chairman of Diagnomics added. “By combining the power of the whole genome microarray with TSI’s PGx knowledge base, Diagnomics’ PGx solution will benefit the whole community from patients to healthcare providers and payers.”

About Diagnomics

Diagnomics Inc. is a trusted provider of innovative genetic testing platforms for both organizations and individual consumers. Diagnomics strives to deliver confidence and reliability by offering comprehensive genomic solutions for the development of personalized healthcare and precision medicine in the global genomics market. Diagnomics is a CLIA-certified, CAP-accredited laboratory providing genetic testing platform services and highly secure HIPAA-compliant cloud-based analysis solutions. To learn more, visit www.diagnomics.com.

About Translational Software Inc.

Translational Software enables healthcare providers to realize the promise of precision medicine. We simplify complex genetic data into evidence-based actionable recommendations to deliver genomic decision support in platform-agnostic formats. Our PGx knowledge base and Fast Healthcare Interoperability Resource (FHIR)-based API has been used to provide over one million PGx recommendations. To learn more, visit us at www.TranslationalSoftware.com.

Source: Diagnomics Inc.